Varicella zoster virus

Human medicines European public assessment report (EPAR): Qutenza, capsaicin, Date of authorisation: 15/05/2009, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Capsaicin, Marketing, European Commission, INN, HIV/AIDS, Infection, Diabetic neuropathy, ATC, Pain, Varicella zoster virus, International, European, Diabetes, Language, Shingles, Red, TRPV1, Trigeminal neuralgia, Neuropathic pain, HIV, Select, Committee, Patient, Risk management, Anatomy, Medicine, IIA, CHMP, Skin, Medical device

Human medicines European public assessment report (EPAR): Qutenza, capsaicin, Date of authorisation: 15/05/2009, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Qutenza, capsaicin, Date of authorisation: 15/05/2009, Revision: 19, Status: Authorised

Microbix & Labquality Create Novel Testing Accreditation Program

Retrieved on: 
Tuesday, June 20, 2023
GUD, HSV, Treponema, Accreditation, Mouth ulcer, EQA, Infection, Mpox, QAP (Colombia), Treponema pallidum, Project management, Varicella zoster virus, OTCQX, TSX, Diagnosis, Disease, Pharmaceutical industry

MISSISSAUGA, Canada and HELSINKI, Finland, June 20, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter and Labquality Oy (Labquality), a global provider of laboratory external quality assessment (“EQA”) programs, announce their creation of the world’s first program to support accreditation of clinical laboratories for detecting the pathogens most commonly causing genital ulcer disease (“GUD”).

Key Points: 
  • This novel Labquality EQA program will help ensure the proficiency of clinical labs testing to diagnose the pathogens that cause GUD.
  • In turn, Labquality has designed and is managing this GUD-oriented EQA program – which is now offered to labs in 60 countries.
  • Juha Wahlstedt, Sales Director at Labquality, commented, “We’re pleased to be employing Microbix’s innovative QAPs for this new and important EQA program.
  • Our expertise was joined to that of Labquality and Copan to ensure accurate testing and properly-directed treatment is widely available for GUD patients.”

Recce Pharmaceuticals to be Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Tuesday, April 11, 2023
Patent, Inhalation, Australian patent law, Veterans' Preference Act of 1944, Cytomegalovirus, HIV, EBV, SARS-CoV-2, Streptococcus pyogenes, Recce, Gonorrhea, Skin, ASX, FSE, Burn, Staphylococcus, Shingles, Escherichia coli, Severe acute respiratory syndrome outbreak, Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae, Simplex, Varicella zoster virus, PCT, Viral disease, Urinary tract infection, Pseudomonas aeruginosa, Administration, Neisseria meningitidis, Patient, Biology, Ross River virus, Viral, Infection, Bacteria, Virus, HCMV, Disease, RCE, Pharmaceutical industry, Vaccine, Proteus, Serratia, Enterococcus

SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We would like to thank the Australian Patent Office for this notification of intent, which further validates the potential of our new class of anti-infectives to help patients with a broad range of bacterial and viral infections,” said James Graham, Chief Executive Officer of Recce Pharmaceutical.
  • Viral infections that may be caused by a range of viruses, such as coated viruses (e.g., lipid-coated viruses), include herpes, human immunodeficiency virus (HIV), cytomegalovirus, and influenza.
  • Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome.

New Data Suggest UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Did Not Increase the Risk of COVID-19 Infection or Reduce Antibody Levels From Childhood Vaccines

Retrieved on: 
Thursday, February 23, 2023
Health, Other Health, COVID-19, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Tetanus, Safety, Civil service commission, Learning, Doctor of Philosophy, Patient, University, Research, Neuroscience, Treatment, Neurology, Risk, Deep vein thrombosis, Great America Committee, NMOSD, Mumps, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MAS, Multiple sclerosis, Infection, History, Rubella, Pulmonary embolism, Varicella zoster virus, Fatality, Measles, European Commission, Incidence, Neuromyelitis optica spectrum disorder, Food, Vaccine, COVID, Pharmaceutical industry

These data suggest UPLIZNA does not increase susceptibility to COVID infection or deplete childhood vaccine-generated antibodies.

Key Points: 
  • These data suggest UPLIZNA does not increase susceptibility to COVID infection or deplete childhood vaccine-generated antibodies.
  • In total, the analysis found a low incidence rate of infections (0.024 events per patient year) among UPLIZNA-treated patients.
  • Of the 10 patients with known outcomes, six were reported as “recovered/resolved,” two as not recovered/resolved and two patients died.
  • “The results of these analyses provide further support that UPLIZNA is an effective long-term treatment for NMOSD with a favorable safety profile.”

Virax Biolabs Introduces Monkeypox Virus Antigen Rapid Test Kit

Retrieved on: 
Tuesday, September 20, 2022
Therapy, Human, COVID-19, Monkeypox virus, Varicella zoster virus, Intention, Nature, Company, Hepatitis B, Growth, Monkeypox, Environment, Forward-looking statement, Patient, Herpes simplex, Technology, CE, Terminology, Diagnosis, Degenerative disease, Board, Union, Skin, Multimedia, View, Vaccine, Malaria

LONDON, Sept. 20, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of a Monkeypox Virus Antigen Rapid Test Kits which has been launched in markets accepting the CE mark, such as the European Union. The test kits are for use in point of care settings and can help healthcare professionals accurately identify a monkeypox infection in people suspected of carrying the monkeypox virus with results typically available in 15 minutes. It also serves as a valuable initial screening test for individuals that have been exposed to monkeypox infected patients or a high-risk environment. The specialized diagnostic kits can be found by contacting the company's sales representatives.

Key Points: 
  • LONDON, Sept. 20, 2022 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of a Monkeypox Virus Antigen Rapid Test Kits which has been launched in markets accepting the CE mark, such as the European Union.
  • The test kits are for use in point of care settings and can help healthcare professionals accurately identify a monkeypox infection in people suspected of carrying the monkeypox virus with results typically available in 15 minutes.
  • Virax's Chairman of the Board and Chief Executive Officer, James Foster commented "I am very proud of our organization's ability to quickly bring this rapid antigen test kit to market to help combat the monkeypox outbreak.
  • The Monkeypox Virus Antigen Rapid Test Kits are used for in vitro qualitative detection of the monkeypox virus antigen in the oropharyngeal (throat) swabs and skin exudates of humans by colloidal gold immunochromatography.

New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+

Retrieved on: 
Wednesday, April 6, 2022
Other Health, Pharmaceutical, Other Consumer, General Health, Women, Infectious Diseases, Seniors, Men, Clinical Trials, Science, Biotechnology, Consumer, Other Science, Health, Research, People, Risk, Company, Face, GSK, Amyris (company), Shingles, VZV, Vaccination, National Drug Code, Diagnosis, Korea Disease Control and Prevention Agency, Vaccine-preventable diseases, CDC, Sex, Plasma protein binding, COVID-19, Encounter, Research, Pain, Publication, Medicaid, Ageing, Varicella zoster virus, Health, Immunity, Chickenpox, MD, Immune system, Infection, Database, Person, Truven Health Analytics, Center, Rash, Annual report, Infectious Diseases Society of America, Patient, Disease, Pharmaceutical industry, Vaccine, Medicare

In this retrospective cohort study, people aged 50 or older who contracted COVID-19 were 15% more likely to develop shingles compared to controls who were never diagnosed with COVID-19.

Key Points: 
  • In this retrospective cohort study, people aged 50 or older who contracted COVID-19 were 15% more likely to develop shingles compared to controls who were never diagnosed with COVID-19.
  • The study observed adults aged 50 years and older using claims data from two large US databases and matched persons with and without COVID-19 using various known shingles risk factors.
  • The study authors, as well as case report publications , suggest that COVID-19 could trigger shingles by disrupting immune cells, allowing VZV to reactivate.
  • Individuals with a first-time COVID-19 diagnosis were matched with controls according to age, sex, shingles risk factors and healthcare costs.

Did CDC Suppress Data on Chickenpox Vaccine? Asks Article in Journal of American Physicians and Surgeons

Retrieved on: 
Tuesday, March 29, 2022
Journal, Shingles, Vaccination, Chickenpox, AAPS, Centers for Disease Control and Prevention, CDC, Physician, Research, Incidence, Immunity, Varicella zoster virus, VASP, Association, GLOBE, Center, Child, Association of American Physicians and Surgeons, Vaccine, Pharmaceutical industry, Surgeon

TUCSON, Ariz., March 29, 2022 (GLOBE NEWSWIRE) -- The chickenpox (varicella) vaccine has markedly decreased the incidence of chickenpox.

Key Points: 
  • TUCSON, Ariz., March 29, 2022 (GLOBE NEWSWIRE) -- The chickenpox (varicella) vaccine has markedly decreased the incidence of chickenpox.
  • Although chickenpox is almost always a mild disease, universal varicella vaccination was adopted in the U.S. primarily based on the cost savings from parental time lost from work to care for a child with chickenpox, according to an article in the spring issue of the Journal of American Physicians and Surgeons.
  • The varicella virus persists in the human body and can later be reactivated to cause a painful case of Herpes zoster (shingles).
  • The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS) , a national organization representing physicians in all specialties since 1943.

Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine

Retrieved on: 
Wednesday, January 5, 2022
Severe cognitive impairment, Elanco, Clinical trial, Shingles, COVID-19, Vaccine, Safety, Herpes simplex, RNA transfection, Development, VZV, HZV, BNTX, News, Varicella zoster virus, Research, Company, Patient, Hoffmann-La Roche, NYSE, Chickenpox, Cancer, Medicine, Infection, Life, Postherpetic neuralgia, Science, Centers for Disease Control and Prevention, U.S. Securities and Exchange Commission, Twitter, Ageing, Paralysis, Annual report, Pierre Geneves, Private Securities Litigation Reform Act, Disease, CEO, PFE, SEC, LinkedIn, Regeneron Pharmaceuticals, BioNTech, PHN, Entrepreneurship, YouTube, Immunotherapy, Technology, Risk, NEW, Nasdaq, Facebook, Deafness, Pharmaceutical industry, Pfizer, Genentech

The collaboration builds on the companies success in developing the first approved and most widely used mRNA vaccine to help prevent COVID-19.

Key Points: 
  • The collaboration builds on the companies success in developing the first approved and most widely used mRNA vaccine to help prevent COVID-19.
  • This is the third collaboration between Pfizer and BioNTech in the infectious diseases field, following the influenza vaccine collaboration initiated in 2018 and the COVID-19 vaccine collaboration initiated in 2020.
  • Pfizer will have rights to commercialize the potential vaccine on a global basis, with the exception of Germany, Turkey and certain developing countries where BioNTech will have commercialization rights.
  • The collaboration aims to develop a new mRNA-based vaccine against shingles, leveraging the expertise and resources of both companies, said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech.

Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine

Retrieved on: 
Wednesday, January 5, 2022
Research, Infectious Diseases, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Severe cognitive impairment, Vaccine, COVID-19, RNA transfection, Cancer, Medicine, Infection, U.S. Securities and Exchange Commission, Twitter, Paralysis, Annual report, Carla Geneve, Disease, SEC, Technology, Shingles, News, Varicella zoster virus, Research, Hoffmann-La Roche, Science, Inc., Private Securities Litigation Reform Act, Regeneron Pharmaceuticals, BioNTech, Nasdaq, Facebook, Deafness, Clinical trial, Safety, Herpes simplex, Development, BNTX, Company, Patient, Life, Ageing, CEO, PHN, Entrepreneurship, Immunotherapy, Risk, Elanco, VZV, HZV, NYSE, Chickenpox, Postherpetic neuralgia, PFE, LinkedIn, YouTube, Multimedia, Pharmaceutical industry, Pfizer, Genentech, Shingles (Herpes Zoster Virus), Pfizer: Breakthroughs That Change Patients’ Lives, BioNTech, SHINGLES (HERPES ZOSTER VIRUS), PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES, BIONTECH

The collaboration builds on the companies success in developing the first approved and most widely used mRNA vaccine to help prevent COVID-19.

Key Points: 
  • The collaboration builds on the companies success in developing the first approved and most widely used mRNA vaccine to help prevent COVID-19.
  • This is the third collaboration between Pfizer and BioNTech in the infectious diseases field, following the influenza vaccine collaboration initiated in 2018 and the COVID-19 vaccine collaboration initiated in 2020.
  • Pfizer will have rights to commercialize the potential vaccine on a global basis, with the exception of Germany, Turkey and certain developing countries where BioNTech will have commercialization rights.
  • The collaboration aims to develop a new mRNA-based vaccine against shingles, leveraging the expertise and resources of both companies, said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech.

Shingrix approved in the US for prevention of shingles in immunocompromised adults

Retrieved on: 
Monday, July 26, 2021
Medical specialties, Chickenpox, Clinical medicine, Medicine, Zoster vaccine, Shingles, Postherpetic neuralgia, Vaccine, Varicella zoster virus, Ramsay Hunt syndrome type 2

Shingrix, a non-live, recombinant sub-unit adjuvanted vaccine, given intramuscularly in two doses, was initially approved by FDA in 2017 for the prevention of shingles in adults 50 years of age or older.

Key Points: 
  • Shingrix, a non-live, recombinant sub-unit adjuvanted vaccine, given intramuscularly in two doses, was initially approved by FDA in 2017 for the prevention of shingles in adults 50 years of age or older.
  • Shingrix is not indicated for prevention of primary varicella infection (chickenpox).The approval for this new population expands the number of people who can be protected against shingles by Shingrix.
  • The GSK Clinical Development Program evaluated the benefit-risk profile of Shingrix in heterogeneous immunocompromised patient populations.
  • Shingrix was previously approved by the European Commission (EC) for prevention of shingles and post-herpetic neuralgia (PHN) in adults 18 years of age or older at increased risk of shingles and granted marketing authorization on August 25, 2020.